Proof-Led Growth in Regulated Healthcare

Sequence evidence against irreversible commitments.

The evidence program should mirror the capital program. An exploratory deployment can establish feasibility and reveal workflow costs. A controlled evaluation can address incremental effect. Repeated delivery across relevant settings can test transferability. These stages answer different questions, and a signed contract, an accreditation or a satisfied sponsor cannot be substituted for the evidence required at another stage.

I would maintain a claim register that connects each commercial assertion to its underlying record, population, comparator, observation window and owner. Where the evidence is observational, the business case should carry the relevant uncertainty rather than quietly converting association into causation. Where an outcome is modeled, the assumptions and sensitivity should travel with the claim into procurement and board materials.

The economic choice is how much capital to commit before uncertainty is resolved. A promising service with low implementation cost and a reversible deployment may justify a bounded test. A proposition requiring permanent staffing, exclusive distribution or major integration should face a higher threshold before expansion. This is not a demand for certainty; it is an allocation of irreversible spending to the strength of the available evidence.

A decision-ready record must also contain adverse findings: nonadoption, failed implementations, missing outcomes, exceptions and customers who declined renewal. Excluding them makes the investment case less useful precisely when leadership needs to understand where the model stops working. I would approve the next commitment only when the remaining uncertainty is explicit, financially tolerable and assigned to a test capable of changing the plan.